SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises Full-Year Guidance
SMS Pharmaceuticals Ltd · Press Release · 05 Nov 2026, 12:05 am
SMS Pharmaceuticals Posts Strong Q2FY27 Results and Raises Full-Year Guidance SMS Pharmaceuticals reported robust Q2FY27 results, with revenue growing 30% YoY and 53% QoQ to ₹316.08 crore, driven by anti-inflammatory APIs and ARVs. EBITDA rose 40% YoY to ₹67.65 crore as margins expanded 145 bps YoY to 21%, while PAT surged 57% YoY to ₹39.57 crore. Management raised its FY27 revenue and EBITDA margin guidance above earlier expectations. The company's ₹280 crore capex program remains on track, with ₹160 crore deployed. Additionally, Ibuprofen capacity is expanding to 9,600 MTPA, and peptide pilot-scale production is slated for Q4FY27.
Original exchange filing (PDF)
More announcements from SMS Pharmaceuticals Ltd
- Earnings Call Transcript · 10 Nov 2026
- Investors Meet Audio Recording · 05 Nov 2026
- Investor Presentation for quarter and half year ended September 30, 2026 · 04 Nov 2026
- Financial results and change in Company Secretary · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about General Updates · 04 Nov 2026
- Change in Management_Company Secretary · 04 Nov 2026
- SMS Pharmaceuticals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer · 04 Nov 2026
- Outcome of Board Meeting and Financial Results · 04 Nov 2026
